TransGenex Nanobiotech, Inc. (aka TGN) is a biotechnology company working on novel polymer-based nanoparticles as platform technologies for drug delivery. Primarily focused on cancer nanotechnology, and developing tests for cancer clinical diagnostic tests for personalized cancer treatment and is developing anti-cancer drugs targeting cancer stem cells, TGN has a strong patent position, developed by the founders and licensed by TGN from the University of South Florida. TGN seeks to: 1) develop a broad-based technology for the nano-encapsulation of therapeutically active compounds, 2) discover and develop nanoparticle formulations to diagnose as well as treat acute and chronic pulmonary inflammatory diseases and cancer. The target market segments include in vitro diagnostics for HIV and cancers, and nanoparticle therapeutics for cancers, asthma and chronic respiratory diseases.
